Roundtables

Remote patient monitoring (RPM) is a key component of digital health, especially in the field of oncology.

Are you struggling to establish digital as a cornerstone of your revenue generation strategy? Then this session is for you!

In a market progressively gravitating toward decentralised, consumer-centric healthcare delivery, the business models we use for virtual care must adapt and grow too. Different approaches are constantly emerging, and there’s no one-size-fits-all solution. 

Neurological disorders, given their intricate nature and often elusive markers, pose a significant challenge to neurologists striving for early diagnosis and effective treatment.

Digital health’s interaction with pharma is evolving; it has to evolve. Join this expert led discussion where we will deep dive into the future of Pharma. Seats are limited so apply now to secure your place.

In an era of digital transformation, the way in which we care and treat patients is fundamentally being altered.

Establishing the effectiveness of your solutions and securing reimbursement can be a daunting task. In the evolving reimbursement landscape, presenting a compelling value proposition and robust evidence base becomes crucial.

‍

‍

As the landscape of pharmaceuticals evolves, understanding and adapting to emerging, tech-enabled patient journeys is critical. Improving these journeys is central to enriching patient experiences and, by extension, improving treatment adherence.

As artificial intelligence gains traction in healthcare, the industry finds itself at a crossroads, torn between the anticipation of AI's vast potential and the concerns surrounding ethical and patient safety issues. Join HealthXL as we deep dive into this session, register now to secure your place.

This session is an invite-only meeting. To find out more please contact us.

‍

With the rise of connected sensor technologies, and wearable devices that can offer objective, continuous patient measurements, healthcare stakeholders are presented with a wealth of opportunities to innovate how we measure health.

Compared to other therapeutic areas, mental health presents itself as an area ripe for sustainable direct-to-consumer (D2C) business models. Join us as we delve into these trends within the digital mental health landscape, and explore effective strategies when going down the D2C route.

Since the inception of medicine, practitioners have been sharing observations and best practices.

With new platform technologies emerging, there is an opportunity to elevate pharma’s digital initiatives to a more flexible and globally compliant framework that can scale across multiple markets and therapy areas. Join your peers in this interactive discussion. Seats are limited so apply now to secure your place.

Artificial Intelligence (AI) is disrupting traditional business models by extracting deeper insights from diverse data sets. Join HealthXL in this meeting to deep dive into this topic with your peers working in this space. Seats are limited so apply now to secure your place.

The patient experience is becoming increasingly recognised as a major component of chronic condition treatment delivery. Join us in this roundtable discussion led by Health Beacon where we will deep dive into this topic. Spaces are limited so apply now to secure your seat.

Cultural context significantly influences perceptions and approaches to mental health conditions.

We have made remarkable progress in oncology treatments, yet, many patients are still grappling with basic, and often preventable, barriers to care.

‍

Life sciences companies and digital health startups are teaming up to improve outcomes and reduce the burden of cardiometabolic diseases. Join HealthXL in this session to deep dive into this topic. Apply now to secure your place.

The consumerisation of healthcare has given rise to a new generation of patient with heightened expectations for seamless and personalised experiences.

Digital health is changing the Medical Affairs (MA) function; the introduction of connected technology alongside drugs provides MA with new methods of reaching patients and their physicians.

‍

Digital health’s interaction with pharma is evolving; it has to evolve. Join us in this exclusive roundtable where we will discuss the highlights from our recent HealthXL Pharma 3.0 report and how pharma can do digital health better in the next few years.

The patient experience is becoming increasingly recognised as a major component of chronic condition treatment delivery. Join us in this roundtable discussion led by Health Beacon where we will deep dive into this topic. Spaces are limited so apply now to secure your seat.

The integration of digital assessments, digital-enabled measures as well as novel digital biomarkers, into clinical trials has created a new era of patient-centric and decentralised trials. Apply now to join your peers in this discussion. Seats are limited so apply now to secure your place.

Point solutions have been the norm for pharma to date. Brands create an app in isolation, often duplicating underlying infrastructure already created for other siloed products elsewhere in the company. Join your peers in this discussion led by Appnovation. Spaces are limited so apply now to secure your place.

Artificial intelligence (AI) is beginning to seep into all aspects of healthcare - but its role as a tool for clinical decision making is still under scrutiny. Apply now to join your peers in this discussion. Spaces are limited so register now to secure your place.

In the face of macroeconomic challenges and a tightening financial landscape, DTx startups are experiencing an intensified competition for investment. Join HealthXl in this peer led discussion to deep dive into this topic. Seats are limited so apply now to secure your place.

In this innovation showcase, Pharma, Medtech and VC will meet 1-2-1 with potential Digital Health partners to discuss mutual challenges they face when building successful collaborations. Seats are limited to 3 Pharma/Medtech/VC and 3 digital health companies so we can pair you 1-2-1. Apply now to book your place!

Digital therapeutics (DTx) are yet to show success at scale with traditional salesforce distribution channels. Apply now to discuss this further with your peers working in this space.

Remote patient monitoring (RPM) technologies can benefit the entire surgical workflow, by allowing preoperative and postoperative monitoring that improves patient experience and reduces the overall cost of care. Apply now to secure your place as we deep dive into this topic.

Digital health care pathways in immunology can become siloed due to the fragmentation of healthcare services and the lack of interoperability among healthcare systems and providers. Apply now to join this session and deep dive into this topic with your peers working in this space.

The benefits of digital technologies in oncology are undeniable; however, effectively demonstrating their value to end users is pivotal for the success of these products. Apply now to join your peers in this interactive discussion. Spaces are limited so apply now to secure your seat.

The primary care model has become a key focus in mental health in the US due to a shortage of therapists and specialists. Join HealthXL in this meeting as we deep dive into this topic. Seats are limited so apply now to secure your place.

When it comes to digital therapeutics (DTx), there are many permutations, and what distinguishes a ‘good DTx’ can be difficult to define in a space that is constantly evolving. Apply now to join HealthXL in this session where we will deep dive into this topic. Apply now to secure your space, seats are limited.

Throughout each phase of a drug's life cycle, it is crucial to optimise both clinical and product value: from pre-launch and launch, to growth, maturity, and eventual decline. Apply now to join your peers to discuss this topic further.

While pharma is beginning to recognise the power of digital mental health tools, it is still challenging to get the true value recognition for these solutions. Join your peers to deep dive into this topic. Seats are limited so apply now to secure your place.

Structuring a deal between pharmaceutical companies and digital therapeutics (DTx) companies can be complex, and the specifics will depend on various factors, including the therapeutic area to which the deal pertains, market size, and development stage of the DTx solution. Apply now to join your peers in this discussion.

In the aftermath of COVID-19, the patient journey has undergone considerable changes as digital tools and technologies have become increasingly integrated into the journey. Seats are limited. Apply now to join your peers in this discussion.

Medical affairs (MA) teams play a critical role in communicating with the wider medical fraternity and commercially supporting pharmacologics. Join us in this session where we will deep dive into this topic. Seats are limited so apply now to secure your place.

Engaging healthcare providers is crucial to drive patient adoption of digital health solutions. Apply now to join HealthXL in this peer to peer discussion.

Whilst the Covid-19 outbreak created strong incentives to go digital, it also demonstrated the value of in-person interactions. Apply now to join this session and dive deeper into this topic with your peers working in this space.

Digital health in oncology is still a very raw and undefined practice with companies still searching for a best approach to put these solutions into the patients' hands. Join this peer-to-peer conversation to deep dive into this discussion.

Digital health’s interaction with pharma is evolving; it has to evolve. Join us in this roundtable to discuss the highlights from the report and how pharma can do digital health better in the next few years.

Curious about what is in store for the future of OTC DTx solutions? Join in the conversation with our expert panel to find out! Spaces are limited so apply now to secure your place.

By reducing hospital admissions, and in-person care services, digital hospital at home solutions are emerging as cost-effective services for health systems. Join HealthXL in this discussion. Apply now to secure your place.

The digital front door is a powerful approach to improve patient engagement and care delivery, but it requires a patient-centric and holistic approach to be successful. Apply now to join HealthXL in this panel discussion with leaders working in this space.

With the proliferation of digital health solutions developed and commercialised by MedTech firms, the volume of healthcare data they generate is expanding rapidly. Apply now to join your peers and discuss this topic further.

The large pharmacy chains model in the US presents pharmacies as a promising distribution channel for Digital Therapeutics (DTx). Apply now to join this discussion with your peers working in this space.

In this innovation showcase, 3 Digital Biomarkers companies working on CNS and cognition assessment will meet 121 with 3 Pharma/Medtech/Investors to discuss mutual challenges when building successful collaborations. Seats are limited to 3  Pharma/Medtech/Investors and 3 Digital Biomarkers companies so we can pair you 1-2-1. Apply now to book your place!

Digital health’s interaction with pharma is evolving; it has to evolve. Join us in this roundtable to discuss how pharma can do digital health better in the next few years.

Despite DTx gaining traction in terms of investment, adoption still remains a challenge, and DTx companies struggle to secure reimbursement. Apply now to join your peers as we deep dive into this topic.

Measuring patient engagement with digital health solutions is crucial to ensure the digital intervention is impactful and helps improve patient outcomes. Join this discussion to dive deeper into this topic with your peers working in this space. Seats are limited to apply now to secure your place.

Extended Reality (XR) is a powerful technology that can be used anywhere, at any time. Join HealthXL in this meeting as we discuss this topic further. Seats are limited so apply now to secure your place.

Whilst digital health startups in oncology have tried to build prosperous partnerships with pharma, there are no outstanding results yet, and it has proven hard to make it work. Seats are limited for this event so apply now to deep dive into this topic with your peers.

In this innovation showcase, 3 Digital Health companies in Oncology will meet 121 with 3 Pharma/Medtech/Investors/Healthcare Providers, to discuss mutual challenges when building successful collaborations. Apply now to join this session as seats are limited.

Due to the lack of industry-wide evidence frameworks for digital health solutions in oncology, regulators' and payers' requirements are usually the same as drugs. Join HealthXL in this meeting to deep dive into this topic.

Unlike other therapeutic areas, mental health evaluation and management can be a bit of an art, and at times relies on subjectivity in the outcomes analysis. Join this meeting to discuss this topic further with others working in this space. Places are limited so apply now to avoid disappointment.

As technology advances in all sectors (e.g. fintech, entertainment, etc), consumer behaviour changes and the expectations on user experience are higher than before. Apply now to secure your place in this meeting where you will dive deeper into this topic with your peers.

Millions of people worldwide suffer from autoimmune conditions such as rheumatoid arthritis (RA), psoriasis, lupus, Crohn's disease, multiple sclerosis, atopic dermatitis, to name a few. Join this meeting to deep dive into this topic in the Immunology Meeting Series. Seats are limited so apply now to secure your place.

In the past few years, digital health solutions have proven to be helpful in preventing and managing cardiometabolic diseases remotely, leading to better  health outcomes and less hospitalizations, emergency visits, and in-office visits.

Why is now the right time to move from DTx point solutions to platforms? How to bring this to life? Join this meeting to discuss this topic further with your peers. Apply now to secure your seat.

How can we help healthcare providers and health systems sift through the universe of digital solutions in mental health? How can digital health companies engage providers? Join this meeting to deep dive into this topic with your peers. Spaces are limited so apply now to secure your place.

It can be hard for HCPs to provide precise medical decisions in autoimmune conditions due to the patient variability and the trigger events not being fully understood. Join other senior leaders in this meeting to discuss this topic further.

Market access and adoption are huge challenges in the DTx and Pharma/Life Sciences industry. Apply now to deep dive into this topic with your peers working in this space.

Health systems have been shocked in a way that has never been seen before with the COVID-19 pandemic. Join HealthXL in this meeting to discuss this topic with your peers working in this space.

Many pharma companies have explored partnerships with DTx companies in the last few years, seeking for innovative technologies that add value to their products and services. Apply now to secure your place in this Digital Health meeting.

The connection between DTx and human coaching in mental health can weave together a more precise, personalized, and connected care experience. Apply now to join this meeting to discuss this topic further with your peers.

In this innovation showcase, Pharma, Medtech, and VC will meet 1-2-1 with potential Digital Health partners to discuss mutual challenges they face when building successful collaborations. Spaces are limited so apply now to secure your place.

Currently, there is no one-size-fits-all strategy for DTx distribution. Join HealthXL in this meeting to discuss this topic further with your peers working in this space.

Without adoption, even the best DTx solution will have no impact. Apply now to join this meeting and discuss this topic further with your peers working in this space

DTx-Drug combinations can improve the treatment value, thus leading to better patient outcomes. Join HealthXL in this session to discuss this topic with thought leaders in this space.

While the number of partnerships between DTx and Pharma have grown in the past years, we haven’t seen big successes yet, and part of that could be due to bad roadmap definition and its execution. Join your peers in this meeting to discuss this topic further

In Neurodegenerative Diseases, aging is a risk factor and as the older populations grow, its prevalence increases, leading to an enormous burden on healthcare systems. Join this meeting to deep dive into this topic with other senior leaders in this field.

Are you struggling to get patients and healthcare professionals (HCPs) to adopt your digital health product? Join this meeting to deep dive into this topic with your peers working in this space.

Oncology services have changed in recent years from the way cancer is diagnosed to how treatment is being delivered. Join other senior leaders in this session to deep dive into this topic.

There is no question that Big Tech has the capability to disrupt healthcare, though the complexity of healthcare ecosystems is not making it easy for these companies. Join this meeting to dive deeper into this topic and discuss how Big Tech is getting into digital health.

Many DTx companies target payers to get reimbursed, but very few vendors get what they are looking for. Join this meeting to deep dive into this topic with other senior leaders in this area.

‍

Cardiovascular diseases (CVD) have been at the forefront of digital health innovations. Join HealthXL in this meeting where we will focus on the use of digital health tools for the prediction of cardiovascular events.

Physician adoption is one of the keys to unlocking the revenues expected from DTx solutions. Join HealthXL in this meeting to discuss this topic with other senior leaders in this field.

‍

In a complex disease area like oncology, treatments usually cause adverse effects that compromise patients' quality of life. Join this session to discuss this topic further with your peers working in this field.

Over the last few years, partnerships between digital therapeutics (DTx) and Life Sciences companies have grown exponentially. Join HealthXL in this meeting to discuss this topic with thought leaders in this area.

Digital health solutions can track a huge amount of data points, but tracking too many different measures can make you lose focus. Join HealthXL in this meeting to discuss this with other thought leaders working in this area.

‍

In this innovation showcase, Pharma, Medtech and VC will meet 1-2-1 with potential Digital Health partners to discuss mutual challenges they face when building successful collaborations. Apply now to book your place in this bilateral discussion.

In a world where customers are used to excellent user experience (e.g. Google, Amazon, Apple, etc.), DTx companies need to meet customers' expectations. Join other senior leaders in this session to discuss what the success metrics of patient engagement are for DTx solutions.

As more DTx-drug combinations emerge, regulation is becoming increasingly important. Join HealthXL in this meeting to dive deeper into this topic.

Digital solutions have great potential in mental health, improving care access, symptom tracking, and treatment personalization. Join HealthXL in this meeting to discuss this topic further with your peers working in this area.

‍

Do you want to network with other innovators and leaders in digital health? Are you looking to identify potential partners? Join us for the new HealthXL style of virtual speed networking and meet other members working in this space!

What are the best models for DTx in the US in this new reality? How will the business models change in the future? Join us in a peer-to-peer conversation where we will discuss these questions and more!

While the digital therapeutics (DTx) market is increasingly growing, it is still small compared to large players in the healthcare industry such as pharma. Join HealthXL in this peer-to-peer discussion to deep dive into this topic.

Join this meeting to take a deep dive into what the best business models will be in the next few years for virtual care companies in the diabetes space.

Pharma companies are huge corporations with complex operations to ensure the quality of their products and services. Join HealthXL in this meeting to deep dive into this topic with others working in this space.

The accelerated growth of the virtual care industry since the pandemic has opened many opportunities for virtual care companies. Join HealthXL in this meeting to dive deeper into this topic and discuss further with your peers working in this space.

Digital therapeutics (DTx) and drugs are very different care solutions. However, DTx are often compared to traditional pharmaceutical products because the terminology and definitions are unclear. Join this meeting to discuss this topic further with your peers.

Most digital health companies in oncology will struggle to get their products in the market on their own. Join HealthXL in this meeting to discuss the do's and don'ts when seeking partnerships for digital health companies in oncology.

Do you want to network with other innovators and leaders in digital health? Are you looking to identify potential partners? Join us for the new HealthXL style of virtual speed networking and meet other members working in this space!

Are you trying to figure out what is the best distribution channel for your digital therapeutics (DTx) solution? Join this meeting to discuss this topic further with your peers working in this space.

Digital health companies can take different routes to market, however, finding the one that is sustainable and scalable in the long term, is not an easy task. Join this meeting to discuss this topic further with others working in this space.

Are you targeting payers as part of your market access strategy? What do you need to know about their evidence requirements for DTx? Join HealthXL in this meeting to discuss this topic further with your peers working in this space.

Are you a digital therapeutics (DTx) start-up seeking capital? How can companies get attention from investors in an increasingly competitive industry? Join HealthXL in this meeting to discuss this topic further with others working in this space.